Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
23 March 2016Website:
http://www.corvuspharma.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 28 Jun 2024 22:35:58 GMTDividend
Analysts recommendations
Institutional Ownership
CRVS Latest News
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) held its Q1 2024 Earnings Conference Call on May 6, 2024 at 4:30 PM ET. Participants included Zack Kubow from Real Chemistry, Richard Miller (President and CEO, Co-Founder), Leiv Lea (Chief Financial Officer), Jeffrey Arcara (Chief Business Officer), James Rosenbaum (Senior Vice President of Research), and Ben Jones (Senior Vice President of Regulatory and Pharmaceutical Sciences). Conference call participants included Jeff Jones from Oppenheimer, Graig Suvannavejh from Mizuho Securities, Liang Cheng from Jefferies, and Rosemary Li from Cantor Fitzgerald. The call provided a business update and reported on the company's financial results for the first quarter of 2024. All lines were in a listen-only mode during the call.
The selling pressure for Corvus (CRVS) may have decreased as it is now considered oversold. Along with this technical indicator, the consensus among analysts on Wall Street raising earnings estimates suggests the stock is ready for a turnaround.
Corvus (CRVS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Corvus (CRVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT
Corvus' (CRVS) lead candidate, soquelitinib, gets orphan drug designation in the United States. The company?
Corvus (CRVS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Here is how Corvus Pharmaceuticals (CRVS) and Cue Biopharma, Inc. (CUE) have performed compared to their sector so far this year.
Here is how Corvus Pharmaceuticals (CRVS) and Journey Medical Corporation (DERM) have performed compared to their sector so far this year.
What type of business is Corvus Pharmaceuticals?
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
What sector is Corvus Pharmaceuticals in?
Corvus Pharmaceuticals is in the Healthcare sector
What industry is Corvus Pharmaceuticals in?
Corvus Pharmaceuticals is in the Biotechnology industry
What country is Corvus Pharmaceuticals from?
Corvus Pharmaceuticals is headquartered in United States
When did Corvus Pharmaceuticals go public?
Corvus Pharmaceuticals initial public offering (IPO) was on 23 March 2016
What is Corvus Pharmaceuticals website?
https://www.corvuspharma.com
Is Corvus Pharmaceuticals in the S&P 500?
No, Corvus Pharmaceuticals is not included in the S&P 500 index
Is Corvus Pharmaceuticals in the NASDAQ 100?
No, Corvus Pharmaceuticals is not included in the NASDAQ 100 index
Is Corvus Pharmaceuticals in the Dow Jones?
No, Corvus Pharmaceuticals is not included in the Dow Jones index
When does Corvus Pharmaceuticals report earnings?
The next expected earnings date for Corvus Pharmaceuticals is 08 August 2024